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Okechukwu et al. recently presented an interesting paper
in this journal on antihypertensive prescription behaviour
in an Irish population [1].The British Hypertension Society
recommends the use of ACE inhibitors, angiotensin II
receptor antagonists or b-adrenoceptor blockers (A or B)
for those under the age of 55 years, and calcium channel
blockers or diuretics (C or D) for those 55 years and older
[2].Okechukwu et al. conclude that the choice of ﬁrst-line
antihypertensivesisgenerallyinlinewiththeseguidelines,
but mainly for those under the age of 55 years [1]. In this
letter, besides some comments, we compare these results
with the Dutch setting.
Okechukwu et al. presented their data in a very
straightforward manner, allowing us to reproduce the
authors’ results. Data were presented as the numbers of
patients and percentages.However in our opinion,report-
ing percentages for male and female patients as fractions
of the total number of patients leads to an underestima-
tion of the true percentage values (for recalculated per-
centage values,see Appendix).A more crucial mistake was
made on the gender speciﬁc analyses.When Okechukwu
et al. reported on the likelihood to receive recommended
therapy for ‘young males vs. old males’, they in fact pre-
sented an odds ratio (OR) for young males vs. young
females.Similarly,theauthorsreportedonthelikelihoodto
receive recommended therapy for ‘old females vs. young
females’,whilethepresentedORwasinfactforoldfemales
vs. old males. It should be noted that we were able to
conﬁrm all other likelihood ratios and 95% conﬁdence
intervals presented by the authors.
Dutch and British guidelines are not identical yet share
similarities. The Dutch General Practitioners Association
(NHG) recommends diuretics for the elderly [3]. Similarly,
the Bureau for Health insurances (CVZ) recommends
diuretics or calcium channel blockers for patients 60 years
and older [4]. No speciﬁc recommendations for young
patients are given in the Netherlands. In the literature,
diuretics and calcium channel blockers have been proven
to be effective in older hypertensive patients [5, 6].While
diabetes is no longer considered a contraindication for the
prescription of b-adrenoceptor blockers [7],ACE inhibitors
are often considered drugs of ﬁrst choice because of their
renal protective effects [8].
To compare Irish and Dutch prescription behaviour
on antihypertensive treatment, we used data from the
population-based IADB, which holds prescription records
of approximately 500 000 people in the Netherlands
(http://www.IADB.nl).Our methods were identical to those
used by Okechukwu et al. [1].In short,we selected all indi-
viduals older than 25 years of age receiving their ﬁrst
antihypertensive monotherapy, excluding those receiving
medication indicating heart disease, and identiﬁed dia-
beticpatientsbyprescriptionofinsulinororalhypoglycae-
mic therapy. Our only alteration from the methods of
Okechukwu et al. was a longer timeframe (between
January 2005 and December 2006) to increase statistical
power.However when the timeframe was restricted to the
length used by Okechukwu et al. (between January 2005
and December 2005),results were similar.Statistical analy-
ses were performed using Microsoft® Ofﬁce Excel 2003.
The data are shown in Table 1.
Young (<55 years) Dutch patients were more likely to
receive antihypertensive therapy A or B (10.3% or 53.9%)
than older Dutch patients were to receive C or D (4.9% or
44.1%), OR 1.86, 95% CI 1.73, 1.99. This OR is higher than
found in the Irish setting (OR 1.31, 95% CI 1.26, 1.37) [1].
Similar to the Irish setting,young males vs. young females
were more likely to receive antihypertensive therapy A or
B, although this reached only borderline signiﬁcance (OR
1.11,95% CI 1.00,1.23).Also similar to the Irish setting,old
females vs. old males were more likely to receive recom-
mended therapy C or D (OR 1.28,95% CI 1.17,1.41).Finally,
Dutch patients receiving antidiabetic therapy were more
likely than nondiabetic patients to be prescribed an anti-
hypertensive drug other than b-adrenoceptor blockers
(OR 4.16,95% CI 3.58,4.83),even more so than in the Irish
setting (OR 2.97,95% CI 2.74,3.21) [1].
A possible explanation for the high agreement
between prescription patterns with guidelines and litera-
ture in the Netherlands can be found in the fact that GPs
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(PTAMs),in which prescription behaviour is discussed and
analyzed.High quality PTAMs have been found to improve
rational pharmacotherapy [9]. Our report that Dutch and
Irish prescribing patterns are similar, although guidelines
are not, supports ﬁndings that prescription patterns are
also inﬂuenced by other factors such as personal experi-
ence,foreignguidelinesorstudiessupportingtheseguide-
lines [10].
Appendix: Table 1 from the paper of Okechukwu et al. [1] with
recalculated percentage values as mentioned in this letter
Table A1
Irish setting:choice of ﬁrst antihypertensives by age and diabetes (expressed as percentage of gender speciﬁc age group or diabetes)
Drug class
Group without cardiovascular comorbidities and diabetes
Under 55 years
(n = 12 745)
55 years or over
(n = 28 683)
Sub-group receiving antidiabetic
therapy (n = 6966)
ACE inhibitor/angiotensin receptor blockers (A) T 2863 (22.5%) 7718 (26.9%) 3253 (46.7%)
M 1311 (28.4%) 3118 (29.0%) 1831 (50.2%)
F 1552 (19.1%) 4600 (25.7%) 1422 (42.8%)
b-adrenoceptor blockers (B) T 4589 (36.0%) 6116 (21.3%) 732 (10.5%)
M 1604 (34.8%) 2313 (21.5%) 384 (10.5%)
F 2985 (36.7%) 3803 (21.2%) 348 (10.5%)
Calcium channel blockers (C) T 1942 (15.2%) 5469 (19.1%) 1197 (17.2%)
M 825 (17.9%) 2143 (19.9%) 607 (16.7%)
F 1117 (13.7%) 3326 (18.6%) 590 (17.8%)
Diuretics (D) T 3351 (26.3%) 9380 (32.7%) 1784 (25.6%)
M 871 (18.9%) 3188 (29.6%) 822 (22.6%)
F 2480 (30.5%) 6192 (34.6%) 962 (29.0%)
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Drug class
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